Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
January 21, 2022, 12:56 am
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the first patient has been dosed in a Phase 2 clinical trial of OPNT002, nasal naltrexone, for the treatment of Alcohol Use Disorder (“AUD”).
